12.04.2022 Marinomed Biotech AG  ATMARINOMED6

DGAP-News: Marinomed Biotech AG signs new agreement for Carragelose in South Korea


DGAP-News: Marinomed Biotech AG / Key word(s): Agreement

12.04.2022 / 07:45
The issuer is solely responsible for the content of this announcement.

Marinomed Biotech AG signs new agreement for Carragelose in South Korea

  • Marinomed wins Hanmi Pharmaceutical Co., Ltd., one of the largest South Korean pharmaceutical companies, as partner for the distribution of Carragelose nasal spray
  • Hanmi obtains an exclusive license for South Korea, the third largest pharmaceutical market in Asia
  • Carragelose, shown to effectively inactivate SARS-CoV-2 wildtype and common variants, is currently available in more than 40 countries worldwide

Korneuburg, Austria, 12 April 2022 - Marinomed Biotech AG (VSE:MARI), an Austrian science-based biotech company with globally marketed therapeutics derived from innovative proprietary technology platforms, announced today that the Carragelose-based nasal spray has been out-licensed for the South Korean market. Marinomed's exclusive license partner is stock-listed Hanmi Pharmaceutical Co., Ltd (128940:Korea SE), headquartered in Seoul. Hanmi Pharmaceutical is one of the leading pharmaceutical South Korean companies with a broad product portfolio in many therapeutic areas and a strong marketing expertise. Under the agreement, Hanmi is responsible for pursuing local approval for the Carragelose nasal spray and will market and distribute the product in South Korea.

"We are delighted to enter into another licence agreement with a strong partner for the marketing of our Carragelose nasal spray in South Korea. With Hanmi Pharmaceutical, we are once more expanding the global presence of our virus-blocker," said Dr. Andreas Grassauer, CEO of Marinomed. "This partnership brings us closer to our goal of making Carragelose accessible to everyone. Carragelose has clinically proven to be safe and highly efficacious in preventing and treating viral respiratory diseases, including COVID-19."

Currently, Carragelose products are available over the counter (OTC) without prescription in more than 40 countries. Carragelose has been well established to prevent respiratory infections by various viruses, including certain influenza virus strains and endemic coronaviruses.[1] Since the beginning of the COVID-19 pandemic, Carragelose has been shown to effectively inactivate both wildtype[2] and common variants[3] of the new coronavirus SARS-CoV-2. Clinical data from an independent study in Argentina had demonstrated an 80 % reduction in PCR-confirmed COVID-19 cases in hospital staff after Carragelose-treatment.[4]

About Carragelose(R):
Carragelose(R) is a sulfated polymer from red seaweed and a unique, broadly active virus-blocking compound. It is known as a gentle, effective, and safe prevention and treatment of various viral respiratory infections. Several clinical and preclinical studies have shown that Carragelose(R) forms a layer on the mucosa that entraps entering viruses, thereby inactivating them, and preventing them from infecting cells. Laboratory and clinical data have shown that Carragelose(R) can also inactivate SARS-CoV-2.1,4 Marinomed is the holder of the IP rights and has licensed Carragelose(R) for marketing in Europe, Canada, Australia, and parts of Asia and Latin America. Marinomed's portfolio of Carragelose(R)-containing nasal sprays and oral products can be accessed at https://www.carragelose.com/en/portfolio/launched-products, scientific publications on Carragelose(R) at https://www.carragelose.com/en/publications.

About Marinomed Biotech AG
Marinomed Biotech AG is an Austrian science-based biotech company with globally marketed therapeutics. Marinomed focuses on the development of innovative products based on two patent-protected technology platforms. The Marinosolv(R) technology increases the solubility and bioavailability of compounds that are hardly soluble in aqueous formulations. Under the brand Solv4U, Marinomed providesformulation development based on the Marinosolv(R) technology for external partners. The Carragelose(R) platform comprises innovative patent-protected products targeting viral infections of the respiratory tract and may also reduce the risk of an infection with SARS-CoV-2. Carragelose(R) is used as a virus blocker in nasal sprays, throat sprays, and lozenges, which are sold via international partners in over 40 countries. Marinomed, Marinosolv(R) and Carragelose(R) are registered trademarks of Marinomed Biotech AG. These trademarks may be owned or licensed in select locations only. The company is based in Korneuburg, Austria, and listed on the Prime Market of the Vienna Stock Exchange (VSE:MARI). Further information is available at https://www.marinomed.com.

For further inquiries contact:

Marinomed Biotech AG
PR: Lucia Mayr-Harting

T +43 2262 90300 158
Email: [email protected]
IR: Stephanie Kniep
T +43 2262 90300 226
Email: [email protected]
International Media Contact
MC Services AG

Dr. Brigitte Keller, Dr. Regina Lutz
T +49 89 210228 0
UK: Shaun Brown
M: +44 7867 515 918
Email: [email protected]

This press release contains forward-looking statements, which are based on current views, expectations and projections of the management of Marinomed Biotech AG about future events. These forward-looking statements are subject to risks, uncertainties and assumptions that could cause actual results, performance or events to differ materially from those described in, or expressed or implied by, such statements. The current views, expectations and projections of the management of Marinomed Biotech AG may be identified by the context of such statements or words such as "anticipate," "believe", "estimate", "expect", "intend", "plan", "project" and "target". Forward-looking statements are only valid as of the date they are made and Marinomed Biotech AG does not assume any obligation to update, review or revise any forward-looking statements contained in this press release whether as a result of new information, future developments or otherwise.


12.04.2022 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language: English
Company: Marinomed Biotech AG
Hovengasse 25
2100 Korneuburg
Phone: +43 2262 90300
Fax: +43 2262 90300-500
E-mail: [email protected]
Internet: www.marinomed.com
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt, Munich, Stuttgart, Tradegate Exchange; Vienna Stock Exchange (Official Market)
EQS News ID: 1318339

End of News DGAP News Service

1318339  12.04.2022 


Die wichtigsten Finanzdaten auf einen Blick
  2016 2017 2018 2019 2020 2021 2022
Umsatzerlöse1 2,61 4,81 4,67 6,14 8,12 11,63 11,28
EBITDA1,2 -1,34 -1,44 -4,90 -5,88 -5,39 -3,54 -4,24
EBITDA-Marge3 -51,34 -29,94 -104,93 -95,77 -66,38 -30,44 -37,59
EBIT1,4 -1,53 -1,64 -5,14 -6,21 -5,82 -4,14 -4,91
EBIT-Marge5 -58,62 -34,10 -110,06 -101,14 -71,67 -35,60 -43,53
Jahresüberschuss1 -1,97 -2,38 -12,10 -7,22 -6,01 -5,89 -6,40
Netto-Marge6 -75,48 -49,48 -259,10 -117,59 -74,01 -50,65 -56,74
Cashflow1,7 -2,53 -2,18 -4,32 -7,64 -6,89 -4,87 -5,20
Ergebnis je Aktie8 -1,97 -2,38 -12,10 -5,10 -4,10 -4,00 -4,30
Dividende8 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2022 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: BDO

Marinomed Biotech
WKN Kurs in € Einschätzung Börsenwert in Mio. €
A2N9MM 43,700 Halten 66,39
KGV 2024e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
0,00 0,00 0,00 -9,44
-15,97 - 5,89 -19,05
Dividende '22 in € Dividende '23e in € Div.-Rendite '22e
in %
0,00 0,00 0,00 21.06.2023
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
23.05.2023 17.08.2023 21.11.2023 19.04.2023
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
19,21% -12,03% -22,24% -40,79%
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu Marinomed Biotech AG  ISIN: ATMARINOMED6 können Sie bei EQS abrufen

Biotechnologie , A2N9MM , MBG , FWB:MBG